Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 7/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.36 |
| ▸ | WNT1 | P04628 | 6/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 5/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3708296 | 1.00 | CTSC (0.38) | CTSCGSK3BDYRK1AWNT1GPR55 | |
| SCHEMBL3740771 | 0.91 | NAMPT (0.40) | GSK3BDYRK1AWNT1ALKMAP4K3 | |
| SCHEMBL3740767 | 0.91 | NAMPT (0.40) | GSK3BDYRK1AWNT1ALKMAP4K3 | |
| SCHEMBL3741178 | 0.85 | FLT3 (0.36) | DYRK1AMAP4K3MAP4K1EP300 | |
| SCHEMBL3741173 | 0.85 | FLT3 (0.36) | DYRK1AMAP4K3MAP4K1EP300 | |
| SCHEMBL3704141 | 0.84 | GSK3B (0.37) | CTSCGSK3BDYRK1AWNT1GPR55 | |
| SCHEMBL3704139 | 0.84 | GSK3B (0.37) | CTSCGSK3BDYRK1AWNT1GPR55 | |
| SCHEMBL3706768 | 0.84 | PSEN1 (0.36) | DYRK1AMAP4K1 | |
| SCHEMBL3706764 | 0.84 | PSEN1 (0.36) | DYRK1AMAP4K1 | |
| SCHEMBL3746191 | 0.84 | USP30 (0.41) | GSK3BDYRK1AWNT1CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012064269-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES | ASTRAZENECA AB (SE) | 2012-05-18 | — | — | WO | claimed |
| WO-2012064269-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES | ASTRAZENECA AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | APP, BACE1, PSEN1 | CTSC 352/4885GSK3B 152/4885DYRK1A 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.